James Smith
Keine laufenden Positionen mehr
Profil
James Smith served as Vice President of Corporate Communications at YM BioSciences, Inc. from 2011 to 2014.
He then worked as Vice President of Business Development at Sierra Oncology, Inc. from 2014 to 2022.
Prior to that, he was Vice President of Corporate Development at SQI Diagnostics, Inc. Mr. Smith received his undergraduate and graduate degrees from Queen's University and an MBA from LaTrobe University.
Ehemalige bekannte Positionen von James Smith
| Unternehmen | Position | Ende |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Investor Relations Kontakt | 01.12.2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Investor Relations Kontakt | 01.01.2014 |
| SQI DIAGNOSTICS INC. | Corporate Officer/Principal | - |
Ausbildung von James Smith
| Queen's University | Graduate Degree |
| LaTrobe University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SQI DIAGNOSTICS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
